🚀 Our landmark study in npj Genomic Medicine shows better outcomes when cancer biology is well-matched: survival doubled (OS 18.7 vs 9.0 mo; HR 0.54, P=0.003) in multivariate analysis validating @CureMatch Score👇Link in comments
Cancer drives massive costs, billions on high-cost, low-value drugs, better evidence could avoid. We rank the best molecularly matched therapies from 4.5M+options for each patient’s unique tumor profile. Higher matching scores→better outcomes+less waste on ineffective treatments
@a16z It’s over $2.6 billion for cancer drug trials. Our Clinical Trial Intelligence platform addresses this whether working directly with BioPharma or with the CROs. @NavidAlipour@Dr_R_Kurzrock@AllyPerlina
Complex molecular changes in cancer shape how tumors grow, respond to treatment, and develop resistance. CureMatch helps cut through that complexity by matching patients to the most effective personalized therapies based on their unique molecular profile. @carisls@Labcorp
Our platform accelerates these trials by using proprietary molecular matching score to evaluate how well investigational therapies address each patient’s full genomic profile—enabling smarter patient stratification, optimized trial design, and higher probabilities of success.
Rare cancers impose a major health burden accounting for roughly 25% of cancer mortality. Early trials are critical, where small patient populations, profound biological heterogeneity & the lack of established standards of care demand data-driven approach to drug development.
@MusicBeatCancer Thank you for your partnership and advocacy @MJhaveriPhD and team! The more awareness of how we can support cancer patients, the more lives we can make an impact on.
🚀 Our landmark study in npj Genomic Medicine shows better outcomes when cancer biology is well-matched: survival doubled (OS 18.7 vs 9.0 mo; HR 0.54, P=0.003) in multivariate analysis validating @CureMatch Score👇Link in comments
@BenjamineYLiu Congrats Ben! What @CureMatch does on the trial intelligence front may be helpful. A discovered asset creates value & questions: Is this the right drug? The right target? Is this the right patient population? Is there a credible clinical path? Is the biology differentiated?..”
@chadinabhan@FoundationATCG Congratulations @chadinabhan on this announcement! We are agnostic as to which labs NGS is done at…we do see a lot of Foundation ones.